Intranasal oxytocin for the treatment of cannabis and alcohol dependence
The effect of intranasal oxytocin on cannabis and associated alcohol cravings and withdrawal in patients diagnosed with cannabis and alcohol dependence
University of Sydney
80 participants
Apr 29, 2010
Interventional
Conditions
Summary
This double-blind, randomised, placebo controlled trial will examine the safety and efficacy of intranasal oxytocin for the treatment of cannabis and alcohol dependence. It is hypothesised that participants randomised to the oxytocin condition, compared to participants randomised to the placebo condition will have a higher rate of treatment completion, experience reduced number, severity, and duration of cannabis and alcohol withdrawal symptoms and will report fewer days of cannabis and alcohol use at one month follow-up.
Eligibility
Inclusion Criteria1
- Diagnostic and Statistical Manual for Mental Disorders-IV diagnostic criteria for cannabis and alcohol dependence.
Exclusion Criteria12
- Epilepsy
- Severe depression with suicidal thoughts and/ or actions
- Drug addiction (other than nicotine, cannabis, or alcohol)
- Currently take medication and you are not stable on this medication (i.e., have been taking the medication for less than 4 weeks)
- Are currently receiving psychological or pharmacological treatment for substance use problems
- Kidney Disease- (i.e., kidney stones, recurrent bladder infections, or known kidney failure).
- Severe liver disease (e.g., decompensated hepatic failure)
- Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate).
- Nasal obstruction, discharge, or bleeding
- Cardiovascular problems (e.g., heart disease, history of heart attacks), high blood pressure (hypertension)
- Habitually drink large volumes of water
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
40 international units of oxytocin intranasally twice per day for 4 weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000742077